8-K: ENDRA Life Sciences Reports Reduced Operating Expenses and Progress in Clinical Trials

ENDRA Life Sciences announced its third quarter 2024 financial results, highlighting a significant reduction in operating expenses and accelerated enrollment in its global multisite pilot study for its TAEUS technology.

Summary

• ENDRA Life Sciences reported its financial results for the third quarter of 2024, showing a net loss of $2.4 million, compared to a $3.1 million loss in the same quarter of 2023.
• Operating expenses decreased by 52% year-over-year to $1.5 million, primarily due to reductions in general and administrative spending.
• The company achieved $3.1 million in annualized savings through cost-cutting initiatives and a refocus on clinical and regulatory activities.
• ENDRA has accelerated subject recruitment for its TAEUS liver fat measurement study, enrolling nearly 40 subjects in the past two months.
• A TAEUS system was activated at LMU University Hospital in Germany for a post-market clinical study.
• The company's intellectual property portfolio expanded to 82 issued patents globally.
• ENDRA submitted a study highlighting TAEUS technology in patients with high BMI for presentation at The Liver Meeting 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to significant cost reductions, progress in clinical trials, and expansion of intellectual property. However, the company is still operating at a loss and has risks associated with regulatory approvals and funding.

Positives

• The company significantly reduced operating expenses, leading to $3.1 million in annualized savings.
• Subject recruitment for clinical trials has accelerated, with nearly 40 subjects enrolled recently.
• ENDRA expanded its intellectual property portfolio with a new patent in Europe.
• The company is actively developing AI, ML, and DL models to enhance the TAEUS platform.
• A TAEUS system was activated at a leading European research center, LMU University Hospital in Germany.
• The company has refocused resources on clinical and regulatory activities to support a De Novo FDA submission.

Negatives

• The company reported a net loss of $2.4 million for the third quarter of 2024.
• The net loss included a non-cash charge of $911,000 related to warrants.
• The company's cash and cash equivalents were $4.7 million as of September 30, 2024.

Risks

• The company's ability to raise additional capital is crucial for its continued operation.
• There are risks associated with obtaining FDA and other regulatory approvals for its medical devices.
• The company depends on third parties for the design and manufacture of its products.
• Market acceptance of ENDRA's technology and competition in the industry pose challenges.
• The company's ability to protect its intellectual property is essential for its success.

Future Outlook

Management intends to hold periodic business update calls to discuss recent events with shareholders, particularly around regulatory, clinical, and commercial developments. The company is focused on securing clinical data to support a De Novo regulatory filing with the FDA and is prioritizing its go-to-market strategy.

Management Comments

• We are laser focused on securing the clinical data necessary to support a new De Novo regulatory filing with the FDA above all other initiatives and are encouraged by the subject recruitment progress at our pilot clinical evaluation sites, said Alexander Tokman, acting Chief Executive Officer of ENDRA.
• In parallel, we are making significant progress with our go-to-market strategy for TAEUS to ensure we are prioritizing the most promising verticals, setting our longer-term vision and business strategy, while significantly reducing operating expenses to extend our cash runway.

Industry Context

The announcement highlights ENDRA's progress in developing its TAEUS technology for assessing liver fat, a significant area of unmet need in the diagnosis and management of steatotic liver disease and MASH. The company's focus on clinical validation and regulatory approval aligns with the broader trend of advancing non-invasive diagnostic tools for chronic liver conditions.

Comparison to Industry Standards

• The company is comparing its TAEUS technology against the gold standard MRI-PDFF, which is a common benchmark for liver fat measurement.
• The company's focus on patients with high BMI addresses a known challenge in the industry, where accurate liver fat assessment is difficult with existing point-of-care solutions.
• Competitors in the non-invasive liver diagnostics space include companies developing ultrasound-based and other imaging technologies, but ENDRA's thermoacoustic approach is unique.
• The company's clinical studies at sites like LMU University Hospital are comparable to other medical device companies seeking to validate their technologies in real-world settings.

Stakeholder Impact

• Shareholders may view the cost reductions and clinical progress positively.
• Employees may be impacted by the restructuring and cost-cutting initiatives.
• Customers and patients may benefit from the development of the TAEUS technology.
• Suppliers and creditors may be affected by the company's financial performance.

Next Steps

• Continue subject recruitment at clinical evaluation sites.
• Present study findings at The Liver Meeting 2024.
• Submit study findings to a peer-reviewed journal.
• Continue development of AI, ML, and DL models for the TAEUS platform.
• Prepare for a De Novo regulatory filing with the FDA.
• Hold periodic business update calls with shareholders.

Key Dates

Keywords

TAEUS, Thermo Acoustic Enhanced UltraSound, liver fat, clinical trials, FDA, De Novo, operating expenses, intellectual property, AI, machine learning, metabolic disease, MASH, steatotic liver disease